
WE CLAIM:

1. A crystalline form of Compound I having the formula



wherein the crystalline form is:

(A)

a. Form A_0; or

b. Form B_0; or a mixture thereof, or

(B)

a. Form HA_0; or

b. Form HC_0; or

c. Form HD_0; or a mixture thereof.

2. A crystalline form of Compound I according to claim 1, wherein the crystalline form is Form A_0.

3. A crystalline form of Compound I according to claim 1, wherein the crystalline form is Form B_0.

4. A crystalline form of Compound I according to claim 1, wherein the crystalline form is Form HA_0.

5. A crystalline form of Compound I according to claim 1, wherein the crystalline form is Form HC_0.

6. A crystalline form of Compound I according to claim 1, wherein the crystalline form is Form HD_0.

7. A process for preparing a crystalline form of Compound I according to claim 1, option (A)(a), comprising the steps of:

    a. Slurrying Compound I in at least one hydrocarbon solvent;
    b. Cooling the resulting slurry;
    c. Filtering the resulting slurry; and
    d. Drying the filter-cake.

8. A process for preparing a crystalline form of Compound I according to claim 1, option (A)(a), comprising the steps of:


    a. dissolving Compound I in a solvent;
    b. filtering the resulting solution;
    c. partially distilling the solvent while adding an anti-solvent to precipitate Compound I;
    d. further distilling the resulting slurry while adding additional anti-solvent to reduce the volume of the solvent used in step (a);
    e. heating the slurry to achieve complete conversion;
    f. cooling;
    g. collecting the product via filtration; and
    h. drying.

9. A pharmaceutical composition comprising a crystalline form of Compound I according to any one of claims 2 to 6, or a mixture thereof.

10. A pharmaceutical composition according to claim 9, wherein the pharmaceutical composition is a mixture thereof.


11. A pharmaceutical composition according to claim 9 or 10 wherein the composition further comprises an amorphous form of Compound I.

12. A process for the preparation of Compound I,




Compound I

comprising the step of reacting Compound A,




Compound A

with 1,1,1-trifluoromethanesulfonic acid 1-cyclopenten-1-yl ester to produce Compound B,




Compound B.

13. A process for the preparation of Compound I




Compound I

comprising the step of reacting Compound C,



Compound C


with maleimide to produce compound D,



Compound D.

CLAIMS

1. A crystalline form of Compound I having the formula



wherein the crystalline form is:

(A)

a. Form A_0 which is characterized by an X-ray powder diffraction pattern comprising one or more of the following peaks: 4.32, 6.07, 8.55, 12.07 and 15.37 ± 0.2 degrees 2-theta; or

(B)

a. Form HC_0 which is characterized by an X-ray powder diffraction pattern comprising one or more of the following peaks: 8.36, 8.71, 16.69, 17.39 and 24.59± 0.2 degrees 2-theta; or

b. Form HD_0 which is characterized by an X-ray powder diffraction pattern comprising one or more of the following peaks: 7.60, 8.99 and 15.16 ± 0.2 degrees 2-theta; or a mixture thereof.

2. A crystalline form of Compound I according to claim 1, wherein the crystalline form is Form A_0.

3. A crystalline form of Compound I according to claim 1, wherein the crystalline form is Form HC_0.

4. A crystalline form of Compound I according to claim 1, wherein the crystalline form is Form HD_0.

5. A pharmaceutical composition comprising a crystalline form of Compound I according to any one of claims 2 to 4, or a mixture thereof.

o o o

6. A pharmaceutical composition according to claim 5, wherein the pharmaceutical composition is a mixture thereof.

7. A pharmaceutical composition according to claim 5 or 6 wherein the composition further comprises an amorphous form of Compound I.

o o o